Recently, Bardia and coworkers reported on 468 patients with or without brain metastases from triple-negative breast cancer who were randomly assigned to receive the trophoblast cell surface antigen 2 (Trop-2) inhibitor sacituzumab govitecan or chemotherapy [5]. This evidence concerns the gene TACSTD2 and triple-negative breast carcinoma.